Determining the key events in the induction of liver cancer in mice by trichloroethylene (TRI) is important in the determination of how risks from this chemical should be treated at low doses. At least two metabolites can contribute to liver cancer in mice, dichloroacetate (DCA) and trichloroacetate (TCA). TCA is produced from metabolism of TRI at systemic concentrations that can clearly contribute to this response. As a peroxisome proliferator and a species-specific carcinogen, TCA may not be important in the induction of liver cancer in humans at the low doses of TRI encountered in the environment. Because DCA is metabolized much more rapidly than TCA, it has not been possible to directly determine whether it is produced at carcinogenic levels. Unlike TCA, DCA is active as a carcinogen in both mice and rats. Its low-dose effects are not associated with peroxisome proliferation. The present study examines whether biomarkers for DCA and TCA can be used to determine if the liver tumor response to TRI seen in mice is completely attributable to TCA or if other metabolites, such as DCA, are involved. Previous work had shown that DCA produces tumors in mice that display a diffuse immunoreactivity to a c-Jun antibody (Santa Cruz Biotechnology, SC-45), whereas TCA-induced tumors do not stain with this antibody. In the present study, we compared the c-Jun phenotype of tumors induced by DCA or TCA alone to those induced when they are given together in various combinations and to those induced by TRI given in an aqueous vehicle. When given in various combinations, DCA and TCA produced a few tumors that were c-Jun؉, many that were c-Jun؊, but a number with a mixed phenotype that increased with the relative dose of DCA. Sixteen TRI-induced tumors were c-Jun؉, 13 were c-Jun؊, and 9 had a mixed phenotype. Mutations of the H-ras protooncogene were also examined in DCA-, TCA-, and TRI-induced tumors. The mutation frequency detected in tumors induced by TCA was significantly different from that observed in TRI-induced tumors (0.44 vs 0.21, p < 0.05), whereas that observed in DCA-induced tumors (0.33) was intermediate between values obtained with TCA and TRI, but not significantly different from TRI. No significant differences were found in the mutation spectra of tumors produced by the three compounds. The presence of mutations in H-ras codon 61 appeared to be a late event, but ras-dependent signaling pathways were activated in all tumors. These data are not consistent with the hypothesis that all liver tumors induced by TRI were produced by TCA. © 2002 Elsevier Science (USA)
Trichloroethylene (TRI) is a common contaminant of ground water as a result of poor disposal practices of the past. As a consequence, this solvent is the focus of many cleanup operations of uncontrolled hazardous waste sites. TRI is carcinogenic in both mice and rats, but at different sites, the liver and kidney, respectively (NCI, 1976; NTP, 1988; NTP, 1990) . Liver tumor induction in mice has been the tumor most critical from the standpoint of environmental regulation (Bull, 2000) . Under the proposed cancer risk guidelines of the U.S. Environmental Protection Agency (EPA, 1996) , identifying the dose-response behavior of key events involved in carcinogenic responses can be used for developing alternative risk assessments.
A major difficulty in developing alternative approaches for assessing risk from TRI is the fact that three of its metabolites are capable of inducing liver cancer in mice Daniel et al., 1992; DeAngelo et al., 1999; Pereria, 1996) . Two of these metabolites have distinct modes of action, dichloroacetate (DCA) and trichloroacetate (TCA). The third metabolite, chloral hydrate, is probably active as a result of its conversion to one or both of these two metabolites. DCA inhibits cell replication and apoptosis (Snyder et al., 1995) but stimu-1 G. A. Orner was supported by Associated Western Universities, Inc., Northwest Division (AWU NW) under Grant DE-FG06-89ER-75522 or DE-FG06-92RL-12451 with the U.S. Department of Energy (DOE). Research was funded by U.S. DOE contract number DE-AC06 -76RL0 1830. A portion of this work was presented at the 37th Annual Meeting of the Society of Toxicology, March, 1998, Seattle, WA. 2 To whom correspondence should be addressed at Washington State University-Tri-Cities, 2710 University Drive, Richland, WA 99352. Fax: (509) 372-7552; E-mail: dbull@tricity.wsu.edu.
lates cell division in tumor cells that are immunoreactive to c-Jun antibodies (Stauber and Bull, 1997) . On the other hand, TCA produces tumors that are uniformly negative with respect to the c-Jun phenotype. This phenotype is consistent with its activity as a peroxisome proliferator (DeAngelo et al., 1989; Nakano et al., 1994) .
Ordinarily, the first approach to assigning causality to a metabolite in tumorigenesis would be an attempt to measure its concentration in the body and associating that with tumorigenic concentrations observed when the compound is itself administered. This can be done with relative ease with TCA (Fisher, 2000; Clewell et al., 2000) . However, it has been shown that DCA administered directly in drinking water induces liver cancer in mice where blood concentrations are below the detection limit. (Kato-Weinstein et al. 1998; Merdink et al., 1998) .
Mutations in the ras protooncogene have been used to determine if distinct patterns of DNA sequence alterations can provide indications of the type of DNA damage that might be produced by carcinogens. The presence of ras mutations in chemically induced tumors was originally suggested as a means of determining whether a chemical was genotoxic (Reynolds et al., 1987) . However, the discovery that spontaneous tumors also contain this oncogene indicated that this assumption was incorrect (Fox and Watanabe, 1985) . Several nongenotoxic carcinogens have been shown to produce liver tumors in male B6C3F1 mice with a mutation frequency considerably below those that result spontaneously. Among these chemicals are peroxisome proliferators . DCA and TRI were found to induce tumors with similar mutation spectra (Anna et al., 1994) , whereas only limited data have been available on TCA (Fereira-Gonzalez et al., 1995) . Schroeder et al. (1997) found H-ras to be rare in liver tumors induced by 3.5 g/L DCA in female B6C3F1 mice and raise questions about the role such mutations play in DCA-induced liver tumors.
In the present study, we examined the question of whether TRI (administered in an aqueous vehicle) induces tumors that carry the c-JunϪ phenotype, which would be predicted if TCA were entirely responsible. We also investigated whether variations in this phenotype could be produced by treating animals with various mixtures of DCA and TCA in drinking water. In addition, the mutation frequency and spectra in the H-ras codon 61 in tumors produced by DCA, TCA, and TRI were investigated to determine whether the hypothesis that TCA alone was responsible for the liver tumors could be supported in this way.
MATERIALS AND METHODS

Materials
DCA was obtained from Fluka Chemical Corporation (Ronkonkoma, NY) and TCA was purchased from Aldrich Chemical Company (Milwaukee, WI). Reagents for PCR and sequencing were purchased from Perkin-Elmer Applied Biosystems (Foster City, CA). All other chemicals were obtained from Sigma Chemical Company.
Experimental Animals
Male B6C3F1 mice were purchased from Charles River Laboratories (Raleigh, NC) at 31-35 days of age with experiments beginning at 6 weeks of age for all experiments. Protocols and animal care were approved by the Institutional Animal Care and Use Committtee at Pacific Northwest National Laboratory. Animals were housed four to six per cage in shoebox cages and had free access to NIH-07 rodent chow and drinking water at all times. Control, TCA, and DCA drinking water solutions were prepared from deionized water and adjusted with sodium hydroxide to pH 7.0 Ϯ 0.2. Animal rooms were maintained on a 12-h light-dark cycle with temperatures controlled to 22-24°C and relative humidity to 35-65%.
Experimental Designs
Experiment 1. After a 1-week acclimation period, animals were randomly assigned to treatment groups and given 0, 0.5, or 2 g/L DCA or 2 g/L TCA in their drinking water for the duration of the study. The doses of DCA were selected to bracket the highest and lowest doses that have produced hepatic tumors without adversely affecting body weight gain. The lowest of these doses result in blood levels of DCA and TCA that roughly match (KatoWeinstein et al., 1998) those produced by administering the lowest dose of TRI that was previously shown to be carcinogenic (Merdink et al., 1998; NTP, 1990) . A subset of mice was sampled after 52 weeks for high doses and associated control mice. Animals treated at 0.5 g/L were treated for an additional 35 weeks and an equal number of control animals were maintained for the same period. Times of euthanasia were selected based upon prior studies that established the appropriate latent periods for liver tumor development at these doses Stauber and Bull, 1997) . Only four animals were lost to miscellaneous causes in this experiment. There was no evidence of treatment-related death. Tumors were identified at necropsy and their diameters were measured in two dimensions (longest and shortest) to obtain a mean diameter. Histopathological examination was limited to 15 randomly selected tumors to ensure that nonneoplastic lesions were not being misclassified.
Experiment 2. DCA and TCA were administered as a mixture to male B6C3F1 mice in drinking water. Twenty animals were assigned to each of 10 groups that received the following concentrations of DCA or TCA in their drinking water for 52 weeks:
The animals were euthanized at 52 weeks, the livers were examined for gross lesions as indicated above, and the histological sections were made for immunostaining and examination by a pathologist. Only two mice were lost during the course of this experiment (one in the 2 g/L DCA group and another in the 0.5 g/L DCA and 0.5 g/L TCA mixture group). Experiment 3. TRI was administered once daily, 7 days per week by gavage in a 5% Alkamuls in distilled water vehicle to a group of 50 mice for a period of 79 weeks. This mode of administration was used because Ͼ10,000 mg/L TRI would be necessary to achieve a carcinogenic dose. Preliminary experiments established that such high concentrations would not be consumed by mice. The use of the Alkamuls vehicle also avoided some of the pharmacokinetic complications associated with corn oil gavage. A control group of 15 mice received an equivalent volume of the vehicle by the same method of administration. At the time of euthanasia, the livers were removed, tumors were identified, the size of the lesions was measured, and the tissues were sectioned for examination by a pathologist and for immunostaining. There were six gavage-associated deaths during the course of this experiment among a total of 10 animals that died with TRI treatment. No animals were lost in the control group.
Tumor Sampling, PCR Amplification, and Sequencing
At the conclusion of each experiment, animals were euthanized, livers were removed, and macroscopically visible lesions (tumors) were identified, measured, and separated from surrounding tissue. A portion of tissue was excised from 25 tumors per treatment group (where available), frozen in liquid nitrogen, and stored at Ϫ80°C until used for ras mutation analysis. Remaining portions of the tumor were either snap-frozen in liquid nitrogen for use in Western blotting or were fixed in 10% neutral buffered formalin for 24 h and then were transferred into 70% ethanol until they were paraffin-embedded and examined histologically. Tumor samples (and samples from liver not including tumors in Experiment 1) for H-ras analysis were digested overnight at 50°C in DNA lysis buffer (50 mM Tris-Cl, pH 8.0; 20 mM NaCl; 1 mM EDTA; 1% SDS; and 1 mg/mL proteinase K), proteinase heat inactivated by boiling, diluted 1:10 in water, and 1-4 L was used as template for PCR amplification. DNA was amplified using a modification of the procedure described by Manjanatha et al. (1996) . The primer pairs GCCGCTGTAGAAGCTATGA and CTTGGTGTTGTTGATGGCAAATACA were used to amplify a 469-bp section of H-ras containing the first and second exon. PCR reaction mixtures contained 4 mM magnesium chloride, 10 mM Tris, 50 mM potassium chloride, 0.2 mM deoxynucleotides, 0.2 M of each primer, and 0.01 U/L Thermus aquaticus DNA polymerase (Perkin-Elmer, Norwalk, CT). A second amplification of an internal sequence containing codon 61 and adding M13 sequence to both ends was then conducted (primers: TGTAAAACGACGGCCAGTA-CAGCCCAGGTCT-TGTA and CAGGAAACAGCTATGACCGTTGATG-GCAAATAC). After amplification, PCR products were purified using Microcon 100 filter units (Amicon, Beverly, MA) and sequenced on an automated cycle sequencer (ABI 377 DNA sequencer). PCR products were sequenced in the forward direction using Perkin-Elmer Applied Biosystems dye primers and confirmed by sequencing in the reverse direction using either dye primer (Experiment 1) or D-rhodamine terminator (Experiment 2) cycle sequencing. DNA from several mutant tumors was reamplified and cloned using a TOPO-TA Cloning Kit (Invitrogen, Carlsbad, CA), providing an additional degree of confidence in the detection of mutations.
Western Blotting
Tumors and adjacent noninvolved liver tissue were homogenized individually in ice-cold homogenization buffer (10 mM KPi, pH 7.5; 0.15 M KCl; 20% glycerol; 1 mM EDTA; 0.5 mM PMSF; 1.9 g/mL aprotinin; 2 g/mL leupeptin; and 200 M sodium orthovanadate). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 10% acrylamide gels (Laemmili, 1970) and electrophoretically transferred to PVDF membranes using a semidry blotter (Emprotech, Natick, MA). Blots were probed with primary antibodies to Ras (Upstate Biotechnology, Lake Placid, NY), Mek (Transduction Laboratories, Lexington, KY), active Erk 1/2 (Promega, Madison, WI), c-Fos, and insulin receptor ␤ (Santa Cruz Biotechnology, Santa Cruz, CA) followed by incubation with a horseradish peroxidase-linked secondary antibody (Biorad, Hercules, CA) and the detection of immunoreactive proteins by chemiluminescence (Amersham ECL kit, Amersham Corp., Arlington Heights, IL).
Analysis
Sequencing chromatograms were compared using Sequencher software (Ver. 3.0, Gene Codes Corporation, Ann Arbor, MI). Western blots were scanned on a flatbed scanner and quantified on a Power Macintosh 7100 using the public domain software NIH Image, Version 1.57. Statistical analyses were conducted using Sigma Stat Version 2.0 (Jandel Scientific, San Rafael, CA) except as otherwise noted. Animal weights were compared by one-way ANOVA followed by the Tukey test for pairwise comparisons. Tumor incidence was compared using Fisher's Exact test. Tumor size, multiplicity, and liver somatic indices were compared using the Kruskal-Wallis nonparametric one-way analysis of variance on ranks. Comparisons of mutation frequencies between treatments were tested for significance by 2 analysis and the mutation spectra were compared using a mutation analysis program described by Cariello et al. (1994) . A p value Յ 0.05 was considered significant.
Immunostaining
The serial liver sections were stained with the c-Jun antibody, SC-45 (Santa Cruz Biotechnology) in a 1 to 25 dilution by methods previously described (Stauber and Bull, 1997) . This antibody was raised against the sequence TPTPTQFLCPKNVTD, which includes Thr 91 and 93 of mouse c-Jun. These residues are phosphorylated by JNK and this activity is thought to lead to dephosphorylation of c-Jun in the DNA-binding domain (Nakano et al., 1994) , which leads to activation of c-Jun as a transcription factor. Therefore, this is potentially a deactivated form of c-Jun that accumulates in liver tumors of male mice (Kato-Weinstein et al., 2001) .
RESULTS
As previously reported , the percentage of body weight made up by liver (liver somatic index) was significantly elevated by DCA or TCA treatment at the doses and periods of treatment that were examined in this study (Table 1) . There were relatively minor effects on body weight. Only in the case of mixed treatments with DCA and TCA and with TRI were there statistically significant effects on body weight. Mice administered TRI for 79 weeks had body weights that were depressed 11% relative to concurrent controls. Administration of TRI in Alkamuls was done to obtain tumors independent of the corn oil vehicle that was used in previous studies. The parallel study using mixtures of DCA and TCA in drinking water was done to determine whether the results obtained with TRI could be accounted for by these metabolites. The effects on body weight and somatic index of the liver in mice treated with TRI, the mixtures of metabolites, and their concurrent controls are also provided in Table 1 . The relatively small tumor burden seen at 52 weeks had little effect on liver weight, so these data indicate that DCA and TCA produce a significant hepatomegaly. Effects seen on liver weight with longer treatment are complicated by increased tumor burdens.
All treatments gave rise to tumorigenic responses in the liver consistent with our past experience. The magnitude of the response to 2 g/L DCA and TCA was about 50% of that seen in past experiments Stauber and Bull, 1997; DeAngelo et al., 1999) . The tumor yield with TRI was slightly higher than was expected from prior NCI (1976) and NTP (1990) bioassays. All gross lesions in this experiment were examined by a pathologist and subjected to sequencing of the H-ras codon 61 and a random sample stained for c-Jun.
Tumor incidence and multiplicity (number of nodules, adenomas, and carcinomas per animal) were significantly higher in animals treated with 2 g/L DCA or TCA for 52 weeks than in control mice (Table 1 ). In addition, tumors were induced in animals treated with 0.5 or 2 g/L DCA for 87 weeks. Mixtures of DCA and TCA increased tumor induction in all combinations. TRI at a daily dose of 1 g/kg per day for 79 weeks also increased the gross tumor response significantly over the concurrent vehicle control. The only treatment that did not in-crease tumor incidence or multiplicity was 0.1 g/L of DCA in drinking water for 52 weeks.
The dose-response relationships between tumor responses produced by DCA or TCA alone or in combination at 52 weeks of treatment are displayed in Fig. 1 . In this figure, the results of both experiments using DCA given alone are combined as being more representative than found in the DCA alone treatment group in the mixture study. The experiments utilizing mixtures of DCA and TCA in drinking water produced responses that were very close to additive when compared to a low dose of DCA (0.1 g/L) was combined with higher dose levels of TCA (0.5 and 2 g/L) when the chemicals were administered alone. However, DCA at 0.5 g/L failed to produce a higher tumor incidence in combination with 2 g/L TCA than was observed with TCA alone. Consequently, the only evidence of an interaction was a smaller number of tumors than would be expected in this latter group. However, the difference between the sum of the responses and that seen in the mixture was not statistically significant. Table 2 displays the pathological characterization of the tumors that were produced in the TRI experiment. Of the tumors identified in control mice for the TRI study, only one was a carcinoma and four were adenomas. These occurred in three animals, giving an incidence of 0.20 at 79 weeks of treatment (Table 2 ). In addition, four histocytic proliferative nodules were identified. One of these was found to be a myelogenous lymphoid lesion. The remaining tumors found in the liver were hyperplastic nodules. TRI treatment significantly Table 2 for more explicit description of incidence data and number of mice per experimental group.
increased the incidence of all three classes of hepatocellular lesions over that observed in control mice. Adenomas were observed at an incidence of 0.64, carcinomas at 0.19, and their combined incidence was 0.75. Several mice had more than one adenoma and/or carcinoma (Table 2) . Histocytic proliferative nodules were observed at the same incidence in TRI-treated and control mice and including these lesions in the total count raises the incidence to 0.83 in the TRI-treated mice.
The pathological characterization of hepatic tumors from mice treated with DCA and TCA and mixtures of these two metabolites are also displayed in Table 2 . The incidence of hyperplastic nodules, hepatocellular adenomas, and hepatocellular carcinomas are reported and the total number of lesions of each type is also provided. The pathology data presented have been confined to those treatments with DCA that were run concurrently with the mixture studies to avoid confusing the results with longer periods of treatment. As previously shown, both DCA and TCA produce dose-related increases in tumor incidence within a 52-week period at doses of 0.5 g/L of drinking water and above. In general, DCA induces a greater number of tumors at a given dose, but a higher fraction of the tumors produced by TCA are hepatocellular carcinomas. Tumor responses with mixed exposures of the two haloacetates were significantly increased in the mixed exposures. In terms of the total tumor yields, the effects appeared to be approximately additive. However, it was notable that the addition of DCA to fixed doses of TCA substantially enhanced the yield of hepatocellular adenomas and produced little, if any, enhancement of the incidence or total numbers of hepatocellular carcinomas. Table 3 indicates the relative frequency at which tumors produced by TRI, DCA, and TCA expressed c-Jun. As previously shown, the c-Jun immunoreactivity found in tumor cells was distributed primarily in the cytosolic compartment when it was present. Earlier work by Stauber and Bull (1997) indicated that the occurrence of a c-JunϪ lesion was diagnostic of TCA, whereas almost all lesions induced by DCA were c-Jun positive. This result was generally borne out in the present study, but a higher proportion of c-Jun tumors were observed when DCA was administered alone. Nevertheless, approximately 50% of DCA-induced tumors were c-Junϩ. When mixtures of DCA or TCA were administered, a large fraction of the tumors displayed a mixed c-Jun phenotype. While half the lesions seen with DCA alone were c-Junϩ, the mixtures gave rise to tumors that were c-Junϩ in one part of the tumor and c-JunϪ in other portions. When TRI was administered, 42% of the lesions displayed a c-Junϩ phenotype, only 34% exhibited a c-JunϪ phenotype, and 24% were of the mixed phenotype. Mutation frequencies and spectra from tumors from animals treated with TRI, DCA, and TCA are shown in Fig. 2 . No mutations were detected in DNA from normal tissue of B6C3F1 mice. Few tumors were observed in control mice sampled at the times examined in this study (nine control tumors were sequenced, of these only two contained a codon 61 mutation). Therefore, for statistical purposes, mutation data from this study were compared to historical control data . However, we have chosen to depict mutation spectra in a way that includes the wild-type sequence (CAA), as it provides a simultaneous view of the mutation frequency in codon 61.
The H-ras codon 61 mutation frequency in tumors of mice differed significantly (p Ͻ 0.05) between TRI and TCA (Fig.  2) . Only 21% of the tumors from TRI-treated animals had a mutation in codon 61, whereas 44% of the tumors from TCAtreated animals had mutations. This difference in mutation frequency was statistically different (p Ͻ 0.05) by Fisher's exact test. Tumors from DCA-treated mice were intermediate in their frequency of H-ras mutations (33%), but this was not significantly different from tumors induced by TRI. In all cases, these frequencies are below the frequency of codon 61 mutations in spontaneous tumors in this strain of mice (56%) . The mutation frequency reported by Ferreira-Gonzalez et al. (1995) was 55% in 11 hepatocellular carcinomas of male B6C3F1 mice treated with 4.5 g/L TCA for 104 weeks. However, the present study utilized lower doses and was of a shorter duration than the Ferreira-Gonzalez study. The mutation spectrum of the TCA-treated animals from the current study is not significantly different from that of the historical controls and the AAA sequence at codon 61 was the most common mutation.
When the H-ras mutation frequencies for all studies of DCA-induced tumors that were conducted below the maximally tolerated dose are analyzed, a clear increase in the H-ras mutation frequency in tumors is seen with time of treatment (or age) (see Maronpot et al., 1995 as well as the data presented in this manuscript). Data from different time points were not available for the TCA and TRI, however.
The H-ras mutations also seem to be a late event in TRIinduced hepatic tumors. In a limited subset of tumors that were both sequenced and classified histologically, only 8 of 34 (24%) of the adenomas contained codon 61 mutations while 9 of 15 (60%) carcinomas contained mutant H-ras at this codon.
The percentage of mutant sequence within each tumor (as judged by the ratio of mutant to wild-type peak heights) was lower than would be expected if the tumors were the result of clonal expansion of cells bearing mutant ras. Most tumors contained less than 50% mutant sequence and only one was completely without wild-type sequence. The average Ϯ SE ranged from 38 Ϯ 5% in the 0.5 g/L DCA treatment group to 49 Ϯ 13% in the 2 g/L DCA for the 87 weeks group. There were no significant differences in this measure classified by treatment duration or dose.
Proteins involved in the MAP kinase-signaling cascade were examined in order to determine if the three common codon 61 mutations of ras had different effects on downstream effectors. Figure 3 contains Western blots of TCA tumor and noninvolved tissue probed with antibodies to ras, Mek, active Erk 1/2, and c-Fos. The antibody used in the current experiment recognized several proteins in mouse liver homogenates. A 28-kDa protein was present as a doublet in nontumor tissue, but in tumor tissue only the higher-molecular-weight protein was present (Fig. 3) . Ras has been reported to migrate as a doublet in Jurkat cells treated with lovastatin, where the faster migrating band was identified as farnesylated, membranebound p21 and the slower migrating band was identified as unprocessed, cytosolic p21 (Goldman et al., 1996) . It is possible that the ras-immunoreactive protein accumulating in TCA and DCA tumors is the unprocessed, inactive form. This is supported by our observation (not shown) that this protein is primarily expressed in the cytosol of tumors. Conversely, our finding that levels of Mek and the dually phosphorylated (active) forms of MAPK (p44Erk1 and p42Erk2) are strongly induced in tumor tissue would not support this view. Each pair (T/NT) is from tumor vs adjacent, noninvolved tissue from the same liver. A ras-immunoreactive protein is present as a single intense band in tumors and as a doublet in the noninvolved tissue (both identified by the single arrow in Fig. 3 ). Mek levels are increased in tumor relative to adjacent tissue, as is phos- phorylation of the MAP kinases Erk 1/2. These differences are also observed in tumors from control and DCA-treated animals. Interestingly, there was no difference in the levels of any of these signaling proteins between different mutation types or even between codon 61 mutant and wild-type tumors. Figure 4 provides information about the cell-signaling environment within DCA-induced tumors relative to surrounding tissue and in tissue from control mice. These data indicate a consistent upregulation of the insulin receptor, ras activation, and ERK 1/2 activity in tumors relative to normal tissue. It is of note that these same changes were seen in tumors that arose spontaneously in control animals as well. Figure 5 provides more direct comparison of insulin receptor expression in the tumor and nontumor portions of liver from mice treated with TRI, TCA, and two concentrations of DCA. It appears that insulin receptor upregulation occurs in most liver tumors induced in the male B6C3F1 mouse relative to normal portions of the liver. Therefore, this parameter does not distinguish between tumors induced by any of these three chemicals.
DISCUSSION
These results strongly suggest that TCA is not solely responsible for liver tumors when mice are treated with TRI. The liver tumor response to TRI has been exclusively attributed to TCA in the past (Elcombe, 1985) . However, the c-Junϩ phenotype is not produced when TCA is administered alone to B6C3F1 mice (Stauber and Bull, 1997) nor by other peroxisome proliferators (Nakano et al., 1994) . Furthermore, the metabolites display the same proclivity for producing a particular phenotype when they stimulate the growth of colonies from suspensions of primary mouse hepatocytes on soft agar (Stauber et al., 1998) . In the TRI-treated mice, two-thirds of the tumors that were immunohistochemically examined expressed the c-Junϩ phenotype exclusively or in part. A caution must be expressed that this result does not necessarily implicate c-Jun in the development of the tumor, because the antibody used in this study recognizes a form of the transcription factor that is largely located in the cytosol that surrounds the nucleus, rather than within the nucleus. Other antibodies gave different patterns to the staining because they interacted differently to phosphorylated and nonphosphorylated forms of the antibody at different epitopes (Kato-Weinstein et al., 2001) .
The detection of a mixed phenotypic expression of c-Junϩ cells with TRI treatment clearly indicates that TCA is not entirely responsible for the liver tumors produced by TRI. When given alone, DCA induced 45-50% c-Junϩ lesions while c-Junϩ lesions have never been observed with TCA. Even higher percentages of tumors were found to express the c-Junϩ phenotype with prior studies (Stauber and Bull, 1997; Richmond et al., 1991) . Since the tumor response seen at 2 g/L DCA in the present study was lower than that seen previous experiments, the greater uniformity of DCA tumors could have been related to the higher tumor yields at this high dose in past studies. Inconsistent findings can be anticipated at the intermediate dose range because blood levels are seen to increase from Ͻ1 M to 300 to 500 M when the concentrations in drinking water are increased from 0.5 to 2 g/L (Kato-Weinstein et al., 1998) . The disproportionate increases in blood levels arise from the fact that DCA is a suicide inhibitor of its own metabolism in mice in this dose range (Gonzalez-Leon et al., 1999) . Thus, the tumor response would be expected to vary in this dose region because relatively small variations in dose (i.e., by drinking more or less water) could result in large variations in the systemic concentrations of DCA.
An unanticipated finding was that the pattern of expression in tumors from mice treated with varying combinations of DCA and TCA did not give rise to tumors with distinct phenotypes but to tumors that displayed the two phenotypes in different parts of the same tumor. While some tumors produced by TRI were found to have a mixed phenotype, a substantial fraction of the tumors that resulted expressed only the c-Junϩ phenotype. The concentrations of DCA and TCA selected for the mixture study should produce approximately the same in vivo ratio and individual peak concentrations of DCA and TCA that would be predicted to arise from the metabolism of a 1-g/kg dose of TRI (Merdink et al., 1998) . These data rule out TCA as the sole cause of liver tumors induced by TRI. Conversely, these data do not prove that the c-Junϩ tumors are entirely the result of metabolism of TRI to DCA or arise from an interaction between the two metabolites. The possibility of a third factor cannot be ruled out. Because of the complexity of the metabolism of TRI, there are several possibilities that could account for this change. One possible candidate is dichlorovinyl cysteine (DCVC). It is possible that the genotoxic effects of this metabolite could contribute to the noncongruence between findings with TRI and mixtures of DCA and TCA. However, DCVC has not been subjected to cancer bioassay in animals.
The expression of both phenotypes in the same tumors produced by TRI or combinations of DCA and TCA is of interest. Do these lesions arise as clones and then the second metabolite "encourages" the growth of mutant cells that arise within the tumor? Alternatively, they could represent the fusion of two distinct lesions that arose independently. The former possibility suggests that exploration of the different portions of these lesions for minimal differences at the genomic level could provide important insights into the question of liver tumor progression. These two compounds may be very convenient models since neither appears to be mutagenic at concentrations that are active in vivo (discussed more fully below).
The H-ras codon 61 mutation frequencies and spectra provided a second test of the hypothesis that TCA was a primary, if not exclusive, contributor to TRI-induced liver tumors in mice. This was based on the simple hypothesis that there should be congruence between the mutation frequency and spectra if TCA were solely responsible for the tumors. Clearly, this was not the case, as the H-ras codon mutation frequency was significantly lower in TRI-induced tumors than in TCAinduced tumors. The mutation frequency seen in DCA-induced tumors was not significantly different from that of TRI, although examination of the data also makes it difficult to attribute the tumors exclusively to DCA. Therefore, these data support the hypothesis that neither metabolite is the exclusive cause of liver tumors in TRI-treated mice.
The contribution of DCA to the liver tumor response in mice has been somewhat controversial primarily because of the very low levels of DCA that are produced in the metabolism of TRI (Merdink et al., 1998) . Minimally effective systemic concentrations of DCA are less than 1 M in the blood of mice (Barton et al., 1999) . The present study suggests that low levels of DCA superimposed on high levels of TCA are additive, at least at low doses. The total tumor response seen at 0.1 g/L DCA and 2 g/L of TCA was not significantly greater than would be expected by the sum of their individual responses. Increasing the concentrations of DCA to 0.5 and TCA to 2 g/L produced a tumor response that was no greater than produced by 2 g/L TCA alone but remained within the confidence limits of the sum of the responses to the independent treatments at these doses. Mutation spectra have been useful for backtracking mechanistically to the adducts to DNA bases produced by genotoxic carcinogens. The utility of mutation spectra for the study of nongenotoxic chemicals is not as clear. The H-ras mutation frequency and spectrum of the tumors from male B6C3F1 mice treated with 2 g/L TCA resembled those of historical controls. This is comparable to what Ferreira-Gonzalez et al. (1995) observed in a limited number of tumors from mice given a higher dose (3.5 g/L) of TCA for 104 weeks. Tumors induced by most other nongenotoxic carcinogens, including phenobarbital, chloroform, and the peroxisome proliferators ciprofibrate and methyl clofenapate, have lower ras mutation frequencies than spontaneous tumors (Fox et al., 1990; Hegi et al., 1993; Stanley et al., 1994) . One notable exception occurred in lesions of female B6C3F1 mice treated with the peroxisome proliferator LY171883, in which the H-ras mutation frequency was 64% (Helvering et al., 1994) . Although LY171883 is a peroxisome proliferator, it activates a different member of the peroxisome proliferator receptor family (PPAR-␥) than does ciprofibrate (Kliewer et al., 1994) . TCA has been shown to activate both PPAR-␣ and PPAR-␥ (Maloney and Waxman, 1999) .
The H-ras mutation frequency of the DCA-induced tumors in this study was lower than reported previously (Anna et al., 1994; Ferreira-Gonzalez et al., 1995) . A number of factors could account for this, including differences in mutation detection methodologies, treatment duration, and/or dose. Our analysis of the H-ras mutation frequency in DCA-induced tumors over time suggests that codon 61 mutations may be late events in male B6C3F1 mice. This is supported by the observation that when the time of euthanasia is considered over all available studies with the frequency of codon 61 H-ras mutations increases with time . It should be noted that treatments of 5 g/L DCA (Fereira-Gonzalez et al., 1995) , which substantially exceeds the maximally tolerated dose in that it results in very substantial decreases in water consumption and losses in body weight does result in a higher mutation frequency in a shorter time period. Moreover, it would be anticipated that a large portion of this group did not survive the treatment to the 76 weeks duration of the study. Therefore, it is likely that these data represent a censored population. In a limited number of tumors that were both sequenced and classified histologically, we observed that the mutation frequency was higher in hepatocellular carcinomas than in adenomas. Anna et al. (1994) also reported a higher frequency of H-ras mutations in carcinomas compared to adenomas in their TRI-and DCA-treated animals, and noted that the expression of H-ras mRNA was highly correlated with malignancy. This is in contrast to studies of strong DNA-alkylating agents for which ras activation appears to be an early event (Wiseman et al., 1986; Watson et al., 1995) . Therefore, these studies indicate that the effects of DCA and TRI are not typical of genotoxic agents. A more likely role is increasing clonal expansion with DNA damage accumulating as the tumor grows in size. This supposition is supported by the observation that the major effect of DCA in liver tumorigenesis is on tumor growth rates (Miller et al., 2000) .
Bacterial mutagenicity assays of DCA and TCA have generally been negative (Bull, 2000) . Recently DCA was found to be weakly, but clearly mutagenic in the mouse lymphoma assay and cytogenetic analyses revealed an increase in chromosome aberrations (Harrington-Brock et al., 1998) . However, these effects occurred at concentrations in the test systems that are several orders of magnitude greater than required for DCA induction of liver cancer (Kato-Weinstein et al., 1998; Merdink et al., 1998) . In the Big Blue transgenic mouse mutagenesis assay, an increased frequency of mutations in the bacterial lacI target gene occurred in mice treated with DCA at 3.5 g/L for 60, but not for 4 or 10 weeks nor with any lower doses (Leavitt et al., 1997) . High doses of DCA (Ն2 g/L in drinking water) cause substantial increases in cell replication within cells with a c-Junϩ phenotype and many small foci of such cells are detected in the liver of mice treated with these high concentrations of DCA (Stauber and Bull, 1997) . Therefore, there are alternative explanations for this observation based upon measurement of DCA's effects on tumor growth rates (Miller et al., 2000) .
Expression and activity of proteins involved in the MAP kinase signaling cascade were measured in order to determine if there were differential effects on this pathway in tumors possessing codon 61 mutations in H-ras. Activation of the MAP kinase cascade occurred in all tumors examined and was independent of H-ras codon 61 mutation status. This is consistent with a recent study by Kalkuhl et al. (1998) in which Raf activity was found to be activated in mouse liver tumors without regard to the H-or K-ras mutation status. Levels of H-ras mRNA have been found to be elevated in tumors of DCA-or TCA-treated mice Richmond et al., 1991) . Nesnow and DeAngelo (1995) also reported that DCA-induced tumors lacking H-ras mutations overexpressed wild-type p21.
Examination of insulin receptor expression revealed that this did not distinguish tumors produced by DCA, TCA, or TRI. In all cases, insulin receptor protein expression was increased in tumor regardless of cause. In the case of DCA treatment, Lingohr et al. (2001) have shown that there is a consistent downregulation of the insulin receptor in normal hepatocytes, an effect that is reproducible in isolated hepatocytes.
In summary, the occurrence of two distinct c-Jun phenotypes of liver tumors in mice treated with TRI is inconsistent with TCA being solely responsible for these tumors. It is probable that DCA contributes to the development of liver tumors in mice treated with TRI, but mixtures of DCA and TCA tend to produce tumors with a mixed phenotype, whereas TRI produced some hepatic tumors that appeared uniformly Junϩ. H-ras codon 61 mutation frequencies and spectra support these conclusions. However, activation of ras-dependent signaling pathways are activated in all hepatic tumors examined irrespective of H-ras mutations.
